Cargando…
Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
Bevacizumab is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with brain metastases could be better-studied. This study examines a population of non-small cell lung cancer (NSCLC) patients with synchronous brain metastases to identify predictors of the decision t...
Autores principales: | Ascha, Mustafa S., Wang, Jacqueline Fang, Kumthekar, Priya, Sloan, Andrew E., Kruchko, Carol, Barnholtz-Sloan, Jill S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882803/ https://www.ncbi.nlm.nih.gov/pubmed/31780762 http://dx.doi.org/10.1038/s41598-019-54513-3 |
Ejemplares similares
-
BSCI-06. FREQUENCY OF BRAIN METASTASIS FROM BREAST AND LUNG CANCER IN THE UNITED STATES -- A POPULATION-BASED ASSESSMENT
por: Ostrom, Quinn, et al.
Publicado: (2019) -
A comparison of relative survival and cause‐specific survival methods to measure net survival in cancer populations
por: Makkar, Nupur, et al.
Publicado: (2018) -
Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex
por: Thierheimer, Marisa, et al.
Publicado: (2023) -
Changes in survival over time for primary brain and other CNS tumors in the United States, 2004–2017
por: Cioffi, Gino, et al.
Publicado: (2022) -
State-of-the-art considerations in small cell lung cancer brain metastases
por: Lukas, Rimas V., et al.
Publicado: (2017)